Skip to main navigation
Skip to search
Skip to main content
Research Explorer The University of Manchester Home
Home
Profiles
Research units
Research output
Projects
Impacts
Activities
Press/Media
Prizes
Equipment
Datasets
Student theses
Search by expertise, name or affiliation
Timothy Illidge, BSc PhD FRCP FRCR FRCPath FMedSci
Prof, ,
Professor of Targeted Therapy & Oncology
,
Division of Cancer Sciences (L5)
https://orcid.org/0000-0003-3191-7324
Email
tim.illidge
manchester.ac
uk
Overview
Fingerprint
Network
Research output
(211)
Projects
(9)
Prizes
(7)
Activities
(48)
Impacts
(5)
Similar Profiles
(6)
Supervised Work
(8)
Research output
153
Article
29
Meeting Abstract
12
Review article
3
Chapter
14
More
3
Letter
2
Anthology
2
Abstract
2
Commentary/debate
2
Editorial
1
Book
1
Paper
1
Preprint
Research output per year
Research output per year
1 results
Publication Year, Title
(descending)
Publication Year, Title
(ascending)
Title
Type
Filter
Paper
Search results
2017
Real World Experience With Brentuximab Vedotin in Relapsed/Refractory CD30 Positive Lymphoma: Outcomes in 33 Patients After Prolonged Follow-up At a Single UK Centre
Piddock, K., Atabani, S., Gibb, A., Bloor, A., Murray, J., Kulkarni, S.,
Illidge, T.
, Linton, K. &
Radford, J.
,
27 Mar 2017
.
Research output
:
Contribution to conference
›
Paper
›
peer-review
File
Allograft
100%
Brentuximab Vedotin
100%
Hodgkin's Lymphoma
75%
Hodgkin Disease
75%
Lymphoma Cell
75%
65
Downloads (Pure)